6/4
08:09 am
aplm
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
High
Report
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
6/4
08:00 am
aplm
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Low
Report
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
5/29
08:00 am
aplm
Apollomics Announces Presentation at the 2024 BIO International Convention
High
Report
Apollomics Announces Presentation at the 2024 BIO International Convention
5/8
04:05 pm
aplm
Apollomics Announces Private Placement Financing and Addition to Board of Directors
Low
Report
Apollomics Announces Private Placement Financing and Addition to Board of Directors
5/8
03:33 pm
aplm
Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $5.00 to $2.00. They now have a "buy" rating on the stock.
Low
Report
Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $5.00 to $2.00. They now have a "buy" rating on the stock.
4/25
08:30 am
aplm
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Low
Report
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
4/10
07:00 am
aplm
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/2
08:00 am
aplm
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Medium
Report
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/1
08:09 am
aplm
Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $17.00 to $5.00. They now have a "buy" rating on the stock.
High
Report
Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $17.00 to $5.00. They now have a "buy" rating on the stock.
3/28
07:00 am
aplm
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
High
Report
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
3/26
08:00 am
aplm
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
Medium
Report
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024